Indication-specific pricing (ISP) is often proposed as a solution to rising healthcare costs, particularly for branded drugs that have multiple indications. But it is unclear whether such a model could work with generic and biosimilar products that have labels from which one or more approved uses have been carved out.
Associate Natasha Daughtrey discusses regulatory and patent infringement issues regarding such products. Read the full article.